Abstract: The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and the use and preparation thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.

Abstract: The present disclosure is directed to oral dosage forms of TR? agonist VK2809 and methods of preparing the same. The disclosure provides oral dosage forms of VK2809 with improved stability and solubility properties that allow for storage under normal conditions through the use of spray-drying with one or more polymers selected from the group consisting of: polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidinone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide) (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), copovidone, poloxamer 407, hypromellose acetate succinate (HPMCAS), polyacrylates and combinations thereof.

Abstract: Disclosed herein are thyroid receptor agonist compounds, polymorphic forms, pharmaceutical compositions, the method of use, and preparation thereof. Some embodiments relate to crystalline forms of Compound 1 and salts thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TR? agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR? agonists with TGF-?-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions. pharmaceutical compositions. the use and preparation thereof.

Abstract: The present disclosure is directed to methods of treating fibrotic conditions by administration of TR? agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR? agonists with TGF-?—dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Abstract: The present disclosure is directed to methods of treating fibrotic conditions by administration of TR? agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR? agonists with TGF-?-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Abstract: The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

Abstract: Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.